Embecta (EMBC) Projected to Post Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) is expected to be issuing its Q1 2026 results before the market opens on Thursday, February 5th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $258.0660 million for the quarter. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings data on Tuesday, November 25th. The company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.04. The business had revenue of $263.30 million during the quarter, compared to analyst estimates of $265.66 million. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.Embecta’s revenue was down 7.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.45 earnings per share. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Price Performance

Shares of EMBC opened at $10.20 on Thursday. Embecta has a 1 year low of $9.20 and a 1 year high of $19.00. The stock’s fifty day moving average price is $12.14 and its two-hundred day moving average price is $12.94. The firm has a market cap of $603.94 million, a PE ratio of 6.26 and a beta of 1.11.

Embecta Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Friday, December 5th were paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date was Friday, December 5th. Embecta’s payout ratio is currently 36.81%.

Analyst Ratings Changes

A number of equities analysts have weighed in on EMBC shares. BTIG Research reiterated a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Wall Street Zen raised shares of Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $18.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Larson Financial Group LLC increased its holdings in shares of Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares during the period. Tower Research Capital LLC TRC increased its stake in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after acquiring an additional 6,224 shares during the last quarter. Wexford Capital LP purchased a new stake in shares of Embecta in the 3rd quarter valued at about $94,000. Humankind Investments LLC bought a new stake in shares of Embecta during the 2nd quarter valued at about $111,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Embecta during the third quarter worth about $115,000. 93.83% of the stock is owned by institutional investors.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.